Shell Asset Management CO Neurocrine Biosciences Inc Transaction History

Shell Asset Management CO

  • $2.9 Billion
  • Q2 2025

A detailed history of Shell Asset Management CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Shell Asset Management CO holds 5,622 shares of NBIX stock, worth $805,126. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,622
Previous 6,012 6.49%
Holding current value
$805,126
Previous $665,000 6.32%
% of portfolio
0.02%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 23, 2025
SELL
$87.54 - $128.18 $34,140 - $49,990
-390 Reduced 6.49%
5,622 $707,000
Q1 2025

May 14, 2025
SELL
$107.22 - $153.29 $24,446 - $34,950
-228 Reduced 3.65%
6,012 $665,000
Q3 2024

Nov 07, 2024
SELL
$114.58 - $153.15 $21,655 - $28,945
-189 Reduced 2.94%
6,240 $719,000
Q1 2024

Jul 31, 2024
SELL
$130.4 - $143.74 $52,029 - $57,352
-399 Reduced 5.84%
6,429 $885,000
Q1 2024

May 14, 2024
BUY
$130.4 - $143.74 $507,908 - $559,867
3,895 Added 132.8%
6,828 $942,000
Q4 2023

Feb 14, 2024
SELL
$106.07 - $132.76 $72,233 - $90,409
-681 Reduced 18.84%
2,933 $386,000
Q3 2023

Nov 08, 2023
SELL
$94.02 - $117.1 $4,324 - $5,386
-46 Reduced 1.26%
3,614 $407,000
Q2 2023

Jul 28, 2023
SELL
$89.53 - $104.87 $76,906 - $90,083
-859 Reduced 19.01%
3,660 $345,000
Q1 2023

May 15, 2023
SELL
$94.11 - $123.02 $1,317 - $1,722
-14 Reduced 0.31%
4,519 $457,000
Q4 2022

Feb 07, 2023
SELL
$106.72 - $127.06 $86,549 - $103,045
-811 Reduced 15.18%
4,533 $541,000
Q3 2022

Nov 14, 2022
SELL
$92.03 - $107.81 $115,681 - $135,517
-1,257 Reduced 19.04%
5,344 $568,000
Q2 2022

Aug 09, 2022
SELL
$75.79 - $100.07 $55,554 - $73,351
-733 Reduced 9.99%
6,601 $643,000
Q1 2022

May 04, 2022
SELL
$72.45 - $94.81 $64,915 - $84,949
-896 Reduced 10.89%
7,334 $688,000
Q4 2021

Feb 09, 2022
BUY
$79.65 - $106.22 $109,200 - $145,627
1,371 Added 19.99%
8,230 $701,000
Q3 2021

Nov 04, 2021
SELL
$86.18 - $99.03 $54,638 - $62,785
-634 Reduced 8.46%
6,859 $658,000
Q2 2021

Aug 12, 2021
SELL
$89.43 - $102.27 $264,086 - $302,003
-2,953 Reduced 28.27%
7,493 $729,000
Q1 2021

May 10, 2021
SELL
$87.57 - $119.4 $929,292 - $1.27 Million
-10,612 Reduced 50.39%
10,446 $1.02 Million
Q4 2020

Feb 16, 2021
BUY
$86.91 - $108.33 $1.01 Million - $1.26 Million
11,654 Added 123.93%
21,058 $2.02 Million
Q2 2020

Aug 10, 2020
SELL
$85.09 - $130.36 $1.02 Million - $1.57 Million
-12,008 Reduced 56.08%
9,404 $1.15 Million
Q1 2020

May 11, 2020
SELL
$75.11 - $113.76 $147,140 - $222,855
-1,959 Reduced 8.38%
21,412 $1.85 Million
Q4 2019

Feb 13, 2020
BUY
$86.8 - $118.57 $471,063 - $643,479
5,427 Added 30.24%
23,371 $2.51 Million
Q3 2019

Nov 12, 2019
SELL
$83.82 - $101.5 $174,010 - $210,714
-2,076 Reduced 10.37%
17,944 $1.62 Million
Q2 2019

Aug 12, 2019
SELL
$72.24 - $91.27 $15,748 - $19,896
-218 Reduced 1.08%
20,020 $1.69 Million
Q1 2019

May 09, 2019
BUY
$69.31 - $91.53 $241,337 - $318,707
3,482 Added 20.78%
20,238 $1.78 Million
Q4 2018

Feb 13, 2019
SELL
$68.32 - $124.36 $223,201 - $406,284
-3,267 Reduced 16.32%
16,756 $1.2 Million
Q3 2018

Nov 13, 2018
SELL
$98.88 - $125.85 $215,459 - $274,227
-2,179 Reduced 9.81%
20,023 $2.46 Million
Q2 2018

Aug 10, 2018
SELL
$75.3 - $105.99 $42,619 - $59,990
-566 Reduced 2.49%
22,202 $2.18 Million
Q1 2018

May 14, 2018
BUY
$75.88 - $92.43 $452,396 - $551,067
5,962 Added 35.48%
22,768 $1.89 Million
Q4 2017

Feb 09, 2018
BUY
$58.53 - $77.59 $304,004 - $403,002
5,194 Added 44.73%
16,806 $1.3 Million
Q3 2017

Oct 20, 2017
BUY
$47.97 - $61.28 $557,027 - $711,583
11,612
11,612 $712,000

Others Institutions Holding NBIX

# of Institutions
683
Shares Held
102M
Call Options Held
290K
Put Options Held
214K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.7B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email